{"title":"Profiling the pattern of medication use during pregnancy: an international scoping review of observational studies.","authors":"Irin Parvin, Hanan Abunimeh, Hisham Alshammari, Amanj Kurdi, Marion Bennie, Tanja Mueller","doi":"10.1080/17512433.2026.2710151","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Medication use during pregnancy has increased significantly worldwide. However, detailed evidence on prescribing patterns during pregnancy remains limited. This scoping review aimed to summarize and provide a comprehensive global overview of the patterns/types of medications used during pregnancy.</p><p><strong>Areas covered: </strong>The Joanna Briggs Institute (JBI) methodology was followed. PubMed, Ovid MEDLINE, Scopus, Web of Science, and EMBASE were searched for population-based and large multicentre observational studies published between January 2010 and April 2024. The included studies focused on pregnant women, investigated and quantified medications use during pregnancy. Identified medications were summarized narratively using the Anatomical Therapeutic Chemical (ATC) and the United States Food and Drug Administration (US-FDA)/Australian Therapeutic Goods Administration (AU-TGA) risk classification systems, and stratified by trimesters.</p><p><strong>Expert opinion: </strong>Of 7,552 studies, 83 were eligible. The most frequently reported ATC categories were alimentary tract and metabolism (A, 0-96%), blood and blood-forming organs (B, 0-84.5%), nervous system (N, 0-73.3%), anti-infectives (J, 0-56%), and respiratory system (R, 0-51.3%). However, limited research provided trimester-specific information. Additionally, risk category A exhibited the widest prevalence range, 0-73.1%, while the higher-risk categories, D and X, were at 0-22.6% and 0-8.3%, respectively. This review highlights the need for further trimester-specific studies.</p>","PeriodicalId":12207,"journal":{"name":"Expert Review of Clinical Pharmacology","volume":" ","pages":"729-747"},"PeriodicalIF":3.6000,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Clinical Pharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17512433.2026.2710151","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/8/3 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Medication use during pregnancy has increased significantly worldwide. However, detailed evidence on prescribing patterns during pregnancy remains limited. This scoping review aimed to summarize and provide a comprehensive global overview of the patterns/types of medications used during pregnancy.
Areas covered: The Joanna Briggs Institute (JBI) methodology was followed. PubMed, Ovid MEDLINE, Scopus, Web of Science, and EMBASE were searched for population-based and large multicentre observational studies published between January 2010 and April 2024. The included studies focused on pregnant women, investigated and quantified medications use during pregnancy. Identified medications were summarized narratively using the Anatomical Therapeutic Chemical (ATC) and the United States Food and Drug Administration (US-FDA)/Australian Therapeutic Goods Administration (AU-TGA) risk classification systems, and stratified by trimesters.
Expert opinion: Of 7,552 studies, 83 were eligible. The most frequently reported ATC categories were alimentary tract and metabolism (A, 0-96%), blood and blood-forming organs (B, 0-84.5%), nervous system (N, 0-73.3%), anti-infectives (J, 0-56%), and respiratory system (R, 0-51.3%). However, limited research provided trimester-specific information. Additionally, risk category A exhibited the widest prevalence range, 0-73.1%, while the higher-risk categories, D and X, were at 0-22.6% and 0-8.3%, respectively. This review highlights the need for further trimester-specific studies.
期刊介绍:
Advances in drug development technologies are yielding innovative new therapies, from potentially lifesaving medicines to lifestyle products. In recent years, however, the cost of developing new drugs has soared, and concerns over drug resistance and pharmacoeconomics have come to the fore. Adverse reactions experienced at the clinical trial level serve as a constant reminder of the importance of rigorous safety and toxicity testing. Furthermore the advent of pharmacogenomics and ‘individualized’ approaches to therapy will demand a fresh approach to drug evaluation and healthcare delivery.
Clinical Pharmacology provides an essential role in integrating the expertise of all of the specialists and players who are active in meeting such challenges in modern biomedical practice.